The modern view of the origin and recurrence of atrial fibrillation

Telegina Anna

Atrial fibrillation is the most common arrhythmia which leads to many complications. Doctors and researchers have great interest in studying this problem. Recently, the attention of researchers is focused on finding new biomarkers involved in initiation and maintenance of recurrences of atrial fibrillation. One of these is galectin-3. Many studies have shown that the concentration of galectin-3 increases during fibrosing processes in different organs, including the myocardium. It takes part in inflammation and cardiac remodeling. Base on these results, we need to find new directions and strategies of treatment. Therefore, using drugs that affect synthesis and metabolism of galectin-3 is a potential new direction of upstream therapy.

Keywords:atrial fibrillation, galectin-3, upstream therapy